Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Sha Zhu, Qifeng Bai, Tingyang Xu
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1038/nrd1468
10.1038/nrd1468
10.1016/j.drudis.2015.05.001
10.1016/j.drudis.2015.05.001
Drug repositioning: a brief overview
10.1111/jphp.13273 · 2020
10.1016/j.ddstr.2011.10.002
10.1016/j.ddstr.2011.10.002
10.1038/nrclinonc.2015.169
10.1038/nrclinonc.2015.169
10.1093/eurheartj/ehw051
10.1093/eurheartj/ehw051
The promise and challenges of drug repurposing in psychiatry
10.1002/wps.20481 · 2018
10.1038/s41564-019-0357-1
10.1038/s41564-019-0357-1
CNS repurposing – Potential new uses for old drugs: Examples of screens for Alzheimer's disease
2019
Drug Repurposing for Rare Diseases: A Role for Academia
10.3389/fphar.2021.746987 · 2021
10.1016/j.tips.2016.01.007
10.1016/j.tips.2016.01.007
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
10.3389/fendo.2017.00006 · 2017
10.1038/nrdp.2015.19
10.1038/nrdp.2015.19
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
10.1200/jco.2016.67.4044 · 2016
Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience
10.1016/bs.pbr.2019.10.008 · 2020
Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease
10.2337/db14-0287 · 2014
10.1161/circresaha.110.223545
10.1161/circresaha.110.223545
10.1056/nejmoa1504720
10.1056/nejmoa1504720
10.1016/j.diabres.2021.109119
10.1016/j.diabres.2021.109119
Current prevalence of Type 1 and Type 2 diabetes in adults and children in the UK
10.1111/dme.12791 · 2015
Incidence of type 1 and type 2 diabetes in adults aged 30–49 years: the population-based registry in the province of Turin
2005
10.1038/emm.2016.7
10.1038/emm.2016.7
10.1111/obr.12298
10.1111/obr.12298
Microvascular Complications of Type 2 Diabetes Mellitus
10.2174/1570161117666190502103733 · 2020
Macrovascular Complications of Type 2 Diabetes Mellitus
10.2174/1570161117666190405165151 · 2020
10.1038/nrd.2018.168
10.1038/nrd.2018.168
10.1038/nbt1284
10.1038/nbt1284
10.3389/fphar.2018.00006
10.3389/fphar.2018.00006
10.1016/j.drudis.2013.07.001
10.1016/j.drudis.2013.07.001
In silico methods for drug repurposing and pharmacology
10.1002/wsbm.1337 · 2016
Data analysis and data mining: current issues in biomedical informatics
10.3414/me11-06-0002 · 2011
10.1038/s41573-019-0024-5
10.1038/s41573-019-0024-5
10.1007/s11095-016-2029-7
10.1007/s11095-016-2029-7
10.1002/minf.201501008
10.1002/minf.201501008
10.1109/tcbb.2021.3091814
10.1109/tcbb.2021.3091814
DeepAffinity: interpretable deep learning of compound-protein affinity through unified recurrent and convolutional neural networks
10.1093/bioinformatics/btz111 · 2019
10.1016/j.neunet.2014.09.003
10.1016/j.neunet.2014.09.003
Comparison of Deep Learning With Multiple Machine Learning Methods and Metrics Using Diverse Drug Discovery Data Sets
10.1021/acs.molpharmaceut.7b00578 · 2017
10.1021/acs.molpharmaceut.6b00248
10.1021/acs.molpharmaceut.6b00248
10.1093/bib/bbaa003
10.1093/bib/bbaa003
10.2337/dci18-0033
10.2337/dci18-0033 · doi-reference
10.1161/circulationaha.114.010389
10.1161/circulationaha.114.010389 · doi-reference
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
10.1161/circresaha.117.311588 · doi-reference
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
10.1016/s2213-8587(19)30249-9 · doi-reference
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
10.1136/bmj.m4573 · doi-reference
10.1161/circulationaha.118.038868
10.1161/circulationaha.118.038868 · doi-reference
10.1056/nejmoa1611925
10.1056/nejmoa1611925 · doi-reference
Repurposing Antidiabetic Drugs for Cardiovascular Disease
10.3389/fphys.2020.568632 · doi-reference
10.1016/j.molmet.2013.11.006
10.1016/j.molmet.2013.11.006 · doi-reference
Diabetes and lipid metabolism
10.1007/s42000-018-0014-8 · doi-reference
Insulin resistance is a cardiovascular risk factor in humans
10.1016/j.dsx.2019.02.023 · doi-reference
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study
10.1136/bmjopen-2020-047993 · doi-reference
Exenatide and the treatment of patients with Parkinson's disease
10.1172/jci68295 · doi-reference
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(17)31585-4 · doi-reference
10.1002/14651858.cd012990.pub2
10.1002/14651858.cd012990.pub2 · doi-reference
10.1111/ejn.15502
10.1111/ejn.15502 · doi-reference
10.1016/j.bbadis.2016.08.018
10.1016/j.bbadis.2016.08.018 · doi-reference
Diabetes drugs in the fight against Alzheimer's disease
10.1016/j.arr.2019.100936 · doi-reference
10.1016/j.pneurobio.2016.10.001
10.1016/j.pneurobio.2016.10.001 · doi-reference
10.3233/jpd-191900
10.3233/jpd-191900 · doi-reference
Type 2 Diabetes Mellitus and Alzheimer’s Disease: Role of Insulin Signalling and Therapeutic Implications
10.3390/ijms19113306 · doi-reference
Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats
10.1002/ijc.28260 · doi-reference
10.1007/s00592-020-01479-8
10.1007/s00592-020-01479-8 · doi-reference
Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma-associated antigen-A3 expression through Yes-associated protein inactivation
10.1002/cam4.3024 · doi-reference
Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
10.3389/fphar.2020.00187 · doi-reference
Sitagliptin May Reduce Breast Cancer Risk in Women With Type 2 Diabetes
10.1016/j.clbc.2016.11.002 · doi-reference
Sitagliptin and oral cancer risk in type 2 diabetes patients
10.18632/oncotarget.18239 · doi-reference
Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes
10.18632/oncotarget.12137 · doi-reference
10.1007/s13340-021-00494-6
10.1007/s13340-021-00494-6 · doi-reference
Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway
10.1016/j.biopha.2020.110821 · doi-reference
10.1002/ijc.31193
10.1002/ijc.31193 · doi-reference
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
10.1016/j.rbmo.2019.04.017 · doi-reference
GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials
10.1007/s12020-020-02223-6 · doi-reference
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials
10.1111/dom.12926 · doi-reference
Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer
10.1186/s12885-018-4570-8 · doi-reference
Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells
10.1530/ec-17-0294 · doi-reference
Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells
10.1210/en.2011-1201 · doi-reference
Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line
10.1016/j.ejphar.2020.173102 · doi-reference
Glyburide attenuates B(a)p and LPS-induced inflammation-related lung tumorigenesis in mice
10.1002/tox.23293 · doi-reference
10.1016/j.bcp.2008.09.009
10.1016/j.bcp.2008.09.009 · doi-reference